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Plasma Clearance of Lovastatin Versus Chinese 
Red Yeast Rice in Healthy Volunteers
ZHAOPING LI, Ph.D., M.D., NAVINDRA P. SEERAM, Ph.D., RUPO LEE, M.Sc., GAIL THAMES, B.A.,
CHAYO MINUTTI, HE-JING WANG, M.P.H., M.D., and DAVID HEBER, Ph.D., M.D.
ABSTRACT
Objectives: It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and sec-
ondary prevention of heart disease. However, the perceived side-effects on muscle and liver reduce the general
acceptance of statin drug therapy as well as compliance over the long term, which is necessary for prevention
efforts to be successful. Chinese red yeast rice (CRYR) is a supplement containing lovastatin (monacolin K),
eight other monacolins, pigments, tannins, and other phytochemicals. The authors previously reported on a dou-
ble-blind placebo-controlled trial of CRYR supplement in 80 individuals demonstrating a significant decrease
in cholesterol levels from 250 mg/dL to 210 mg/dL over 8 weeks independent of diet. The current study com-
pared the pharmacokinetics of CRYR with lovastatin at the same bioeffective dose for lowering cholesterol.
Methods: Eleven (11) healthy volunteers were randomized to a crossover study taking 2400 mg CRYR or
20 mg of lovastatin.
Results: The Cmax and area under the curve (AUC) of lovastatin were 22.42 ng/mL, and 80.47 higher than
CRYR (p  0.001 and 0.002, respectively). The Cmax for lovastatin hydroxy-acid was 36.63 ng/mL higher than
the Cmax of CRYR hydroxy-acid (p  0.001). The AUC of lovastatin hydroxy-acid was 258.5 greater than that
of CRYR (p  0.001).
Conclusions: The results suggested that the effect of CRYR on the cholesterol concentration might be caused
by the additive and/or synergistic effects of monacolin K with other monacolins and substances in CRYR. It
may lead to the ultimate development of a botanical supplement based on CRYR.
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INTRODUCTION
It is now accepted that inhibition of cholesterol biosyn-thesis is effective in the primary and secondary preven-
tion of heart disease. Statin drugs, which are competitive in-
hibitors of HMG-CoA reductase, lower cholesterol levels
and reduce the progression of atherosclerotic lesions while
also stabilizing pre-existing atheromatous plaques. The per-
ceived side-effects on muscle and liver reduce the general
acceptance of statin drug therapy as well as compliance over
the long term, which are necessary for prevention efforts to
be successful.1 Surveys demonstrate that many Americans
often turn to alternative herbal therapies for heart disease
prevention rather than taking drugs,2,3 and view these as nat-
ural alternatives to drug therapy.
Chinese red yeast fermented on rice is a traditional food
consumed throughout Asia. Its food value and medicinal value
date back prior to its first recorded use in 800 AD.4,5 A die-
tary supplement of Chinese red yeast rice (CRYR) has been
prepared that contains only a selected strain of Monascus pur-
pureus Went yeast and white rice on which it was fermented.
There are a number of constituents in the supplement includ-
ing pigments, fatty acids, and polyketides (monacolins).6
The authors previously reported on a double-blinded
placebo-controlled trial of this CRYR supplement in 80 in-
dividuals demonstrating a significant decrease in cholesterol
levels from 250 mg/dL to 210 mg/dL over 8 weeks inde-
pendent of diet.7 The current study was designed to com-
pare the pharmacokinetics of CRYR with lovastatin at the
same bioeffective dose for lowering cholesterol to determine
whether the body metabolizes complex mixtures of natural
substances found in CRYR differently than lovastatin.
METHODS
Subjects
The study protocol was approved by the Ethics Commit-
tee of the University of California, Los Angeles and con-
ducted at the General Clinical Research Unit (GCRC) of
University of California, Los Angeles. Eleven (11) volun-
teers ages 25 to 45 year were recruited for the study. Writ-
ten consent was obtained. All participants were in good
health according to medical history, physical examination,
electrocardiogram, and clinical laboratory measurements
(serum chemistry, liver function tests, and hematology).
Subjects were excluded if they were smokers, tobacco users,
or taking any medication including over-the-counter med-
ications within 14 days prior to the study.
Study design
This was an open label, randomized, crossover study with
a 1-week washout period between two phases. The previous
study had demonstrated that 2400 mg of CRYR is a rele-
vant comparison dose to 20 mg of lovastatin for lowering
blood cholesterol.7
Kantola et al.8 reported that grapefruit increased the
serum levels of lovastatin (Cmax) approximately 12-fold and
the area under the concentration-time curve (AUC) 15-fold
by inhibiting CYP3A4-mediated first-pass metabolism in
the small intestine. The present study uses the preceding
method to increase the detectable levels of monacolins.
The subjects were given 200 mL of double-strength
grapefruit juice (Minute Maid frozen concentrated grape-
fruit juice, 12 fluid ounces (355 mL), Coca-Cola Foods,
Houston, TX) three times per day (at 7 AM, noon, and 8 PM)
for 2 days. On day 3, the subjects reported to the GCRC at
7:30 AM after fasting from 11 PM the previous day. A caf-
feine-free standardized breakfast was served at 7:45 AM and
either 20 mg of lovastatin or 2400 mg of Chinese red yeast
rice was given with 200 mL of double-strength grapefruit
juice at 8 AM. Standardized lunch and dinner were served at
noon and 5 pm. The subjects returned to the GCRC the next
morning to have their blood last drawn at 8 AM.
Sample collection
On the day of administration of lovastatin or CRYR, a
forearm vein of each subject was cannulated with a plastic
cannula and kept patent with a heparin flush. Blood sam-
ples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24
hours after taking lovastatin or taking CRYR. Whole blood
was centrifuged immediately and plasma transferred to plas-
tic tubes and frozen at 80°C until assay.
Methodology for determination of monacolin 
K (lovastatin) and lovastatin hydroxy-acid 
in human plasma
Lovastatin 20–mg capsules were purchased from Merck
& Co. Inc. (Whitehouse, NJ) CRYR dietary supplement 600-
mg capsules were provided by Beijing WBL Peking Uni-
versity Biotech Co., Ltd, China.
HPLC-MS analyses were carried out on an LCQ Classic
Finnigan LC-MS/MS system (ThermoFinnigan, San Jose,
CA), equipped with a HP 1100 series HPLC system consist-
ing of an autosampler and injector, quaternary pump, column
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FIG. 1. High performance liquid chromatography trace of mona-
colins. 1, Monacolin Kanalogue; 2, Monacolin K dehydro ana-
logue; 3, Hydroxy-acid form of Monacolin L; 4, Hydroxy-acid
form of Monacolin K; 5, Dihydromonacolin K; 6, Monacolin L;
7, Hydroxy-acid form of dehydromonacolin K; 8, Monacolin K; 9,
Methyl ester of hydroxy-acid form of monacolin K; 10, Dehy-
dromonacolin K. AU, absorbance.
TABLE 1. CONSTITUENTS OF CHINESE RED YEAST RICE
(LOT NUMBER 20030401)
Rice starch 73.4%
Fiber 0.8%
Protein 5.8%
Moisture ca.6%
Pigments 0.3%
Ash 3%
Phosphorus 0.4%
Organic phosphorus 0.02%
Fatty acids 1.1%
Trace elements
Ca 0.443 mg/g
Mg 1.094 mg/g
Al 78 g/g
Fe 50 g/g
Mn 19 g/g
Cu 8.6 g/g
Ag 20.7 g/g
Pb 1 ppm
Monacolins 0.4%
heater, and diode array detector (DAD). Data handling was
carried out using Xcalibur 1.2 software (ThermoFinnigan).
Conditions for detection were as follows: Column, Symme-
try C-18, 100 mm  2.1 i.d., 3.5 m, (Waters Corp., Milford,
MA); Solvent A) 0.5% acetic acid/acetonitrile, B) 0.5% acetic
acid/water; binary linear gradient system: 0–15 min: 50% A
in B to 90% A in B; 15–18 min, 90% A in B; flow rate 0.2
mL/minute; injection volume 20 L; column temperature
25°C. Mass spectrometer (MS) parameters: The MS (elec-
trospray ionization; ESI) was operated in the negative mode
for the first 11 minutes and then in the positive mode for the
rest of the analytical run; scan range: 115–500 amu; scan rate:
1 scan/sec; cone voltage: 17 eV. Peak identities for lovastatin,
lovastatin hydroxy-acid, and simvastatin were obtained by
comparison of their LC-MS/MS ions with their standards.
Each C8 SPE cartridge was preconditioned with methanol
(2  1 mL) and water (2  1 mL). Each plasma sample 
(400 L) was loaded onto the cartridge and allowed to free-
flow by gravity. Each cartridge was then eluted with con-
secutive aliquots of 1 mL water, 1 mL 5% formic acid, and
then 1 mL of water. The cartridge was allowed to drip dry,
left to stand for 1 minute, then eluted with 1 mL methanol:
water (7:3 v/v) solution, and finally with 1 mL of acetoni-
trile. The combined acetonitrile eluates were evaporated to
dryness in vacuo at low temperature, reconstituted in the
HPLC mobile phase (100 L), vortexed for 1 minute, and
injected onto the LC column for LC-MS analyses.
Plasma calibration standards of lovastatin and its hy-
droxy-acid were prepared by spiking control human plasma
with known concentrations of working solutions of the stan-
dards. Samples were processed according to the extraction
procedure and injected on to the HPLC-MS. Concentrations
were determined from the peak area by using the equation
for linear regression obtained from the calibration curve. The
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FIG. 2. A. Liquid chromatography-mass spectrometry (LCMS)
trace of lovastatin (monacolin K) standard. The molecular ion is
at m/z 427  [M  Na] as reported.9 B. LCMS trace of lovas-
tatin (monacolin K) hydroxy-acid standard. The molecular ion at
m/z 421  [M–H] as reported.9 C. LCMS trace of simvastatin
standard. The molecular ion is at m/z 441  [M  Na] as re-
ported.9
A B
C
calibration curve was linear (R2  0.9954 for lovastatin and
0.9927 for lovastatin hydroxy-acid, respectively) over the
concentration range from 0.1 to 100 ng/mL. The lower level
of quantitation (LOQ) established from the calibration curve
by LCMS was 0.1 ng/mL based on 400 L of plasma. Sim-
vastatin was used as an internal standard as previously re-
ported.9
Statistical analysis
The pharmacokinetic parameters, peak plasma concen-
tration (Cmax), time to peak plasma concentration (Tmax),
and time for appearance of the drug in plasma were obtained
by observation. The AUC from 0 to 24 hours after dosing
was calculated by the linear trapezoidal rule. Elimination
half-life (t1/2) was estimated by 0.693/, where  is the ab-
solute value of the slope of a least-square linear regression
of plasma drug concentration (in natural logarithm scale)
over time at the terminal phase.
The pharmacokinetic parameters of lovastatin and lovas-
tatin hydroxy-acid were tabulated using mean  SEM for
taking lovastatin and CRYR, respectively. This was a 2-by-
2 crossover study with 7-day washout period. No carryover
effect was identified, and no significant period and sequence
effects were found; therefore, signed rank test was used to
compare the pharmacokinetic parameters for Lovastatin ver-
sus CRYR.
All tests used were two sided with a significance level of
0.05. Statistical software SAS was used to carry out the
analysis.
RESULTS
Characterization of the constituents of CRYR
This botanical dietary supplement consists mainly of rice,
and by-products of fermentation. The main groups of con-
stituents are shown in Table 1. Clearly the most abundant
ingredient is starch, constituting over 73% of the bulk. The
protein content is 6%. The other ingredients are found in
much less quantity. Trace elements were analyzed by atomic
absorption spectroscopy. Magnesium is the most abundant
metal with 1094 g/g of rice.
The typical HPLC trace for the monacolin mixture as
found in CRYR is shown in Figure 1 and the Liquid Chro-
matography—Mass Spectrometry (LC-MS) traces of mona-
colin K, monacolin K hydroxyl-acid, and simvastatin stan-
dards are shown in Figures 2A–C, respectively. Figure 3
shows the LC-MS trace of a plasma sample obtained from
a human subject with simvastatin added as internal standard
where monacolin K and monacolin K hydroxy-acid were de-
tected. There is 1.23 mg of monacolin K in every capsule
by assay of manufacture and 1.15 mg by HPLC analyses
under the same conditions.
Pharmacokinetics
The mean values and pharmacokinetics for lovastatin and
CRYR are summarized in Table 2 and the mean plasma con-
centration versus time profiles for monacolin K and mona-
colin K hydroxy-acid are shown in Figures 4A,B, respec-
tively. Monacolin K was detected in plasma 30 minutes after
ingestion of either lovastatin or CRYR. The peak concen-
tration reached at approximately 3 hours. The Cmax and AUC
of lovastatin are 22.42 ng/mL, and 80.47 higher than CRYR
with p value of 0.001 and 0.002, respectively. The dose-nor-
malized Cmax and AUC of lovastatin are 0.89  0.22 ng/mL,
and 3.41  0.99 higher than CRYR with p value of 0.001
and 0.002, respectively.
Monacolin K hydroxy-acid was detected 30 minutes af-
ter taking lovastatin or CRYR but peaked at 4 hours, 1 hour
later than when monacolin K peaked. The Tmax for lovas-
tatin and CRYR hydroxy-acids were similar (p  1.00,
signed rank test). The Cmax for loavstatin hydroxy-acid is
36.63 ng/mL higher than the Cmax of CRYR hydroxy-acid
(p  0.001, signed rank test). The AUC of lovastatin hy-
droxy-acid is 258.5 larger than that of CRYR (p  0.001).
After normalization for dose, the AUC of lovastatin is still
7.21 larger than that of CRYR (p  0.001).
The individual sample for minor monacolins were not de-
tectable by LC-MS/MS. However, the pooled plasma sam-
ples collected from three subjects showed the presence of
minor monacolins reported to be present in CRYR.10 Sam-
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FIG. 3. LCMS trace of human plasma sample showing mona-
colin K hydroxy-acid (tr  9.47 min, base peak m/z 319.06 from
molecular ion at m/z 421); Monacolin K (tr  12.47 min, base peak
m/z 325.24 from molecular ion at m/z 427); Simvastatin (tr  14.46
min, base peak at m/z 325.12 from molecular ion at m/z 441.3) ac-
cording to a previous report.9
ples from all subjects were analyzed after pooled with two
subjects. All the analysis showed the same pattern of minor
monacolins. The data from one analysis are shown in Fig-
ures 5 and 6. Because of the unavailability of standards for
these minor monacolins, Selected Ion Monitoring (SIM) was
conducted in negative and positive ESI modes of CRYR,
and then followed by MS-MS analyses of ions correspond-
ing to each monacolin peak (Figs. 5 and 6). Peak identities
were obtained by matching their molecular ions (M  H)
or (M  Na) obtained by ES-MS/MS ions with expected
values.10 Figure 5A shows the LCMS trace of the CRYR
extract in negative mode with corresponding MS/MS ions
for monacolin K hydroxy-acid (tR 11.38 min; M  H m/z
421), dehydromonacolin K hydroxy-acid (tR 8.36 min; M 
H m/z 403), monacolin L hydroxy-acid (tR 9.49 min; M 
H m/z 321) and dihydromonacolin K hydroxy-acid (tR 14.10
min; M  H m/z 423). Figure 5B shows the LCMS trace of
the pooled human plasma sample with ions corresponding
to monacolin L hydroxy-acid (tR 9.49 min; M  H m/z 423)
and dihydromonacolin K hydroxy-acid (tR 14.09 min; M 
H m/z 423). Similarly, Figure 6A shows the LCMS trace of
the CRYR extract in positive mode with corresponding
MS/MS ions for monacolin K (tR 14.47 min; M  Na, m/z
427), dihydromonacolin K (tR 17.26 min; M  Na, m/z
429), monacolin L (tR 13.28 min; M  Na, m/z 327), and
dehydromonacolin K (tR 18.90 min; M  Na, m/z 409). Fig-
ure 6B shows the LCMS trace of pooled plasma sample with
ions corresponding to dehydromonacolin K (tR 18.82 min;
M  Na, m/z 409). 
DISCUSSION
In 1979, Endo11 reported that a strain of Monascus yeast
naturally produces a substance that inhibits cholesterol syn-
thesis, which he named monacolin K, as well as a family 
of eight monacolin-related substances with the ability to in-
hibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase. In addition to the inhibitors of HMG-CoA re-
ductase, red yeast rice has been found to contain sterols 
(-sitosterol, campesterol, and stigmasterol), tannins, poly-
ketide pigments, sapogenin, isoflavones and isoflavone gly-
cosides, and monounsaturated fatty acids.11,12
CRYR has been shown to lower cholesterol in animals
fed diets designed to induce hypercholesterolemia.13,14 In a
double-blind placebo-controlled and diet-controlled study,
CRYR was demonstrated to lower serum cholesterol by 23%
in 40 hypercholesterolemic patients compared to 40 patients
LOVASTATIN VERSUS RED YEAST RICE 1035
FIG. 4. A. Plasma concentration versus time profile for monacolin K. B. Plasma concentration versus time profile for monacolin K
hydroxy-acid.
TABLE 2. CMAX, TMAX, AND AUC0–24H (MEAN  SEM)
Lovastatin Lovastatin hydroxy-acid
Lovastatin Chinese red yeast rice Lovastatin Chinese red yeast rice
Cmax 23.67  4.56 1.25  0.26 40.94  2.51 4.31  0.79
Tmax 2.77  0.28 3.05  0.24 3.82  0.12 3.82  0.30
AUC0–24h 83.64  21.35 3.17  0.81 287.97  26.78 29.47  6.08
Tlag 0.75  0.15 1.25  0.28 0.80  0.14 1.02  0.12
t1/2 1.22  0.04 2.15  0.16 2.60  0.40 1.45  0.14
AUC, area under the curve.
A B
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FIG. 6. A. Selected ion monitoring (SIM) spectra of the Chinese red yeast rice (CRYR) extract in positive mode with corresponding
MS/MS ions for monacolin K (tR 14.47 min; M  Na, m/z 427), dihydromonacolin K (tR 17.26 min; M  Na, m/z 429), monacolin
L (tR 13.28 min; M  Na, m/z 327), and dehydromonacolin K (tR 18.90 min; M  Na, m/z 409). B. SIM spectra of pooled human
plasma sample with ion corresponding to dehydromonacolin K (tR 18.82 min; M  Na, m/z 409).
A B
100
80
60
R
el
at
ive
a
bu
n
da
nc
e
40
20
6.06 7.30
RT: 6.00-15.00 SM: 15G
7.90 9.59 10.32
11.38
14.71
13.4312.7511.88
11.47
11.95
10.66
9.47
7.93
6.15 8.08 9.15 10.05 12.88
14.10
8.53
11.41
13.87
10.999.93
9.37
8.36
6.43 6.97 14.04 14.88
100
80
60
R
el
at
ive
a
bu
n
da
nc
e
40
20
100
80
60
R
el
at
ive
a
bu
n
da
nc
e
40
20
0
0
6 7 8 9 10 11 12 13 14 15
Time (min)
100
80
60
R
el
at
ive
a
bu
n
da
nc
e
40
20
NL: 2.27E8
m/z = 318.7-319.7
F: −c ESI Full ms2
421.00@35.00
[115.00-450.00] MS
RYR_S104
NL: 1.22E6
m/z = 384.5-385.5
F: −c ESI Full ms2
403.00@35.00
[110.00-430.00] MS
RYR_S104
NL: 3.09E5
m/z = 214.8-215.8
F: −c ESI Full ms2
321.00@43.00
[85.00-350.00] MS
RYR_S104
NL: 1.90E7
m/z = 318.8-319.8
F: −c ESI Full ms2
423.00@45.00
[115.00-450.00] MS
RYR_S104 6.60 7.85
14.09
11.41
8.32
7.62
RT: 6.00-15.00 SM: 15G
9.496.31
0
6 7 8 9 10 11 12 13 14 15
Time (min)
100
80
60
R
el
at
ive
 
a
bu
n
da
nc
e
40
20
10
90
70
50
30
0
100
80
60
R
el
at
ive
 a
bu
n
da
nc
e
40
20
10
90
70
50
30
NL: 1.88E4
m/z = 214.8-215.8
F: −c ESI Full ms2
321.00@43.00
[85.00-350.00] MS
RYR Total02
NL: 2.85E4
m/z = 318.8-319.8
F: −c ESI Full ms2
423.00@45.00
[115.00-450.00] MS
RYR Total02
FIG. 5. A. Selected ion monitoring (SIM) spectra of the Chinese red yeast rice (CRYR) extract in negative mode with correspond-
ing MS/MS ions for monacolin K hydroxy-acid (tR 11.38 min; M  H m/z 421), dehydromonacolin K hydroxy-acid (tR 8.36 min; M 
H m/z 403), monacolin L hydroxy-acid (tR 9.49 min; M  H m/z 321), and dihydromonacolin K hydroxy-acid (tR 14.10 min; M–H m/z
423). B. SIM spectra of the pooled human plasma sample with corresponding MS/MS iosn for monacolin L hydroxy-acid (tR 9.49 min;
M–H m/z 321) and dihydromonacolin K hydroxy-acid (tR 14.09 min; M–H m/z 423).
A B
given placebo.7 The monacolins in CRYR and drug statins
are competitive inhibitors of HMG CoA reductase, the reg-
ulatory enzyme of cholesterol synthesis.15
The current study showed that the quantity of monacolin
K contained in CRYR is much lower and is inadequate to
explain the magnitude of cholesterol lowering observed in
the previous study. The 2400 mg CRYR used in this study
contains only 4.6 mg, 23% of monacolin K of 20 mg lo-
vastatin. The findings of this study demonstrated that the
plasma concentrations of monacolin K and its hydroxy-acid
form are much higher after ingestion of lovastatin than
CRYR. The mixture of monacolins and other substances pre-
sent in the red yeast rice may have some inhibitory effect
on cholesterol biosynthesis. Pooled plasma collected from
three subjects showed the presence of additional minor
monacolins that are known to be present in red yeast rice.10
Various synthetic statins have different degrees of bio-
logic activity, and it is possible that the family of monacol-
ins in CRYR may have a different profile of cellular or mol-
ecular actions. In the current study the monacolin K to
monacolin K hydroxy-acid ratio was 1.72 for lovastatin and
3.48 for CRYR, which further suggests possible different
metabolism. At 72 hours after administration, approximately
83% of lovastatin was excreted in stool and 10% in urine.16
Similar studies of the bioavailability and bioactivity of
CRYR monacolins were not performed previously but
would increase the understanding of the metabolism of this
botanical dietary supplement.
Whereas the proprietary product used in this study was
demonstrated to lower cholesterol levels significantly in
clinical trials, other products being sold as CRYR dietary
supplements have not undergone similar evaluation. Nine
proprietary CRYR supplements were analyzed and it was
found that the total monacolin content can vary from 0% to
0.58% w/w, only 1/9 preparations had the full complement
of 10 monacolin compounds.17
Most of the pharmacokinetic data reported for statins in
the literature have been generated using the HMG-CoA re-
ductase assay to determine total and active inhibitors of
HMG-CoA reductase.18 Although this enzymatic method
can determine the entire latent and active drug and metabo-
lites of lovastatin, it is not chemically specific. In contrast,
the LC-MS/MS method used for determining plasma drug
concentrations in this study is more sensitive and spe-
cific.9,19 By using LC-MS/MS methodology, lovastatin was
detectable a half hour after the 20-mg dose was adminis-
tered.
The benefits of statin drugs on the primary prevention of
heart disease20,21 and in the secondary prevention of recur-
rent heart disease22,23 have been shown in several large,
prospective clinical trials. These studies have increased in-
terest in the prophylactic use of statins for heart disease pre-
vention for individuals with hypercholesterolemia. The Na-
tional Cholesterol Education Program (NCEP) guidelines
were updated recently about pharmacologic intervention.
NCEP is now advocating more aggressive therapy for patients
with high and moderate risks.24 Although it is acknowledged
that side-effects with statins are rare, there are data indicat-
ing that some statins may cause liver function abnormalities
and, under certain circumstances, rhabdomyolysis in a dose-
related fashion.25 Combined use of different statins in lower
doses may decrease the incidence of side-effects.
CONCLUSIONS
In summary this study demonstrated significantly lower
serum monacolin K level for CRYR compared to equiva-
lent cholesterol-lowering dose of lovastatin. CRYR may
serve as a safe and effective natural alternative for people
with modest elevation of cholesterol. The effect of red yeast
rice on the cholesterol concentration is not caused by mona-
colin K alone but the combination of monacolin K and other
monacolins, substances in the red yeast rice supplement.
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